Kintor Pharmaceutical Balance Sheet Health
Financial Health criteria checks 4/6
Kintor Pharmaceutical has a total shareholder equity of CN¥458.1M and total debt of CN¥247.1M, which brings its debt-to-equity ratio to 53.9%. Its total assets and total liabilities are CN¥869.2M and CN¥411.1M respectively.
Key information
53.9%
Debt to equity ratio
CN¥247.10m
Debt
Interest coverage ratio | n/a |
Cash | CN¥458.05m |
Equity | CN¥458.11m |
Total liabilities | CN¥411.12m |
Total assets | CN¥869.23m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: KNTP.F's short term assets (CN¥472.6M) exceed its short term liabilities (CN¥224.7M).
Long Term Liabilities: KNTP.F's short term assets (CN¥472.6M) exceed its long term liabilities (CN¥186.4M).
Debt to Equity History and Analysis
Debt Level: KNTP.F has more cash than its total debt.
Reducing Debt: KNTP.F's debt to equity ratio has increased from 25.8% to 53.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: KNTP.F has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: KNTP.F has less than a year of cash runway if free cash flow continues to reduce at historical rates of 19.6% each year